Copyright Reports & Markets. All rights reserved.

Global Tyrosine Kinase Inhibitors Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Tyrosine Kinase Inhibitors Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Tyrosine Kinase Inhibitors Market Size Growth Rate by Product
      • 1.4.2 BCR-ABL Tyrosine Kinase Inhibitor
      • 1.4.3 Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
      • 1.4.4 Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
    • 1.5 Market by End User
      • 1.5.1 Global Tyrosine Kinase Inhibitors Market Size Growth Rate by End User
      • 1.5.2 Chronic Myeloid Leukemia (CML)
      • 1.5.3 Lung Cancer
      • 1.5.4 Breast Cancer
      • 1.5.5 Renal Cell Cancer
      • 1.5.6 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Tyrosine Kinase Inhibitors Market Size
      • 2.1.1 Global Tyrosine Kinase Inhibitors Revenue 2014-2025
      • 2.1.2 Global Tyrosine Kinase Inhibitors Sales 2014-2025
    • 2.2 Tyrosine Kinase Inhibitors Growth Rate by Regions
      • 2.2.1 Global Tyrosine Kinase Inhibitors Sales by Regions
      • 2.2.2 Global Tyrosine Kinase Inhibitors Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Tyrosine Kinase Inhibitors Sales by Manufacturers
      • 3.1.1 Tyrosine Kinase Inhibitors Sales by Manufacturers
      • 3.1.2 Tyrosine Kinase Inhibitors Sales Market Share by Manufacturers
      • 3.1.3 Global Tyrosine Kinase Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.2 Tyrosine Kinase Inhibitors Revenue by Manufacturers
      • 3.2.1 Tyrosine Kinase Inhibitors Revenue by Manufacturers (2014-2019)
      • 3.2.2 Tyrosine Kinase Inhibitors Revenue Share by Manufacturers (2014-2019)
    • 3.3 Tyrosine Kinase Inhibitors Price by Manufacturers
    • 3.4 Tyrosine Kinase Inhibitors Manufacturing Base Distribution, Product Types
      • 3.4.1 Tyrosine Kinase Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Tyrosine Kinase Inhibitors Product Type
      • 3.4.3 Date of International Manufacturers Enter into Tyrosine Kinase Inhibitors Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Tyrosine Kinase Inhibitors Sales by Product
    • 4.2 Global Tyrosine Kinase Inhibitors Revenue by Product
    • 4.3 Tyrosine Kinase Inhibitors Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Tyrosine Kinase Inhibitors Breakdown Data by End User

    6 North America

    • 6.1 North America Tyrosine Kinase Inhibitors by Countries
      • 6.1.1 North America Tyrosine Kinase Inhibitors Sales by Countries
      • 6.1.2 North America Tyrosine Kinase Inhibitors Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Tyrosine Kinase Inhibitors by Product
    • 6.3 North America Tyrosine Kinase Inhibitors by End User

    7 Europe

    • 7.1 Europe Tyrosine Kinase Inhibitors by Countries
      • 7.1.1 Europe Tyrosine Kinase Inhibitors Sales by Countries
      • 7.1.2 Europe Tyrosine Kinase Inhibitors Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Tyrosine Kinase Inhibitors by Product
    • 7.3 Europe Tyrosine Kinase Inhibitors by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Tyrosine Kinase Inhibitors by Countries
      • 8.1.1 Asia Pacific Tyrosine Kinase Inhibitors Sales by Countries
      • 8.1.2 Asia Pacific Tyrosine Kinase Inhibitors Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Tyrosine Kinase Inhibitors by Product
    • 8.3 Asia Pacific Tyrosine Kinase Inhibitors by End User

    9 Central & South America

    • 9.1 Central & South America Tyrosine Kinase Inhibitors by Countries
      • 9.1.1 Central & South America Tyrosine Kinase Inhibitors Sales by Countries
      • 9.1.2 Central & South America Tyrosine Kinase Inhibitors Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Tyrosine Kinase Inhibitors by Product
    • 9.3 Central & South America Tyrosine Kinase Inhibitors by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Tyrosine Kinase Inhibitors by Countries
      • 10.1.1 Middle East and Africa Tyrosine Kinase Inhibitors Sales by Countries
      • 10.1.2 Middle East and Africa Tyrosine Kinase Inhibitors Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Tyrosine Kinase Inhibitors by Product
    • 10.3 Middle East and Africa Tyrosine Kinase Inhibitors by End User

    11 Company Profiles

    • 11.1 AstraZeneca
      • 11.1.1 AstraZeneca Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 AstraZeneca Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 AstraZeneca Tyrosine Kinase Inhibitors Products Offered
      • 11.1.5 AstraZeneca Recent Development
    • 11.2 Pfizer
      • 11.2.1 Pfizer Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Pfizer Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Pfizer Tyrosine Kinase Inhibitors Products Offered
      • 11.2.5 Pfizer Recent Development
    • 11.3 Novartis
      • 11.3.1 Novartis Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Novartis Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Novartis Tyrosine Kinase Inhibitors Products Offered
      • 11.3.5 Novartis Recent Development
    • 11.4 Bristol-Myers Squibb
      • 11.4.1 Bristol-Myers Squibb Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Bristol-Myers Squibb Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Bristol-Myers Squibb Tyrosine Kinase Inhibitors Products Offered
      • 11.4.5 Bristol-Myers Squibb Recent Development
    • 11.5 Bayer
      • 11.5.1 Bayer Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Bayer Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Bayer Tyrosine Kinase Inhibitors Products Offered
      • 11.5.5 Bayer Recent Development
    • 11.6 Boehringer Ingelheim International
      • 11.6.1 Boehringer Ingelheim International Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Boehringer Ingelheim International Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Boehringer Ingelheim International Tyrosine Kinase Inhibitors Products Offered
      • 11.6.5 Boehringer Ingelheim International Recent Development
    • 11.7 F. Hoffmann-La Roche
      • 11.7.1 F. Hoffmann-La Roche Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 F. Hoffmann-La Roche Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 F. Hoffmann-La Roche Tyrosine Kinase Inhibitors Products Offered
      • 11.7.5 F. Hoffmann-La Roche Recent Development
    • 11.8 Johnson & Johnson
      • 11.8.1 Johnson & Johnson Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Johnson & Johnson Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Johnson & Johnson Tyrosine Kinase Inhibitors Products Offered
      • 11.8.5 Johnson & Johnson Recent Development
    • 11.9 Eisai
      • 11.9.1 Eisai Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Eisai Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Eisai Tyrosine Kinase Inhibitors Products Offered
      • 11.9.5 Eisai Recent Development

    12 Future Forecast

    • 12.1 Tyrosine Kinase Inhibitors Market Forecast by Regions
      • 12.1.1 Global Tyrosine Kinase Inhibitors Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Tyrosine Kinase Inhibitors Revenue Forecast by Regions 2019-2025
    • 12.2 Tyrosine Kinase Inhibitors Market Forecast by Product
      • 12.2.1 Global Tyrosine Kinase Inhibitors Sales Forecast by Product 2019-2025
      • 12.2.2 Global Tyrosine Kinase Inhibitors Revenue Forecast by Product 2019-2025
    • 12.3 Tyrosine Kinase Inhibitors Market Forecast by End User
    • 12.4 North America Tyrosine Kinase Inhibitors Forecast
    • 12.5 Europe Tyrosine Kinase Inhibitors Forecast
    • 12.6 Asia Pacific Tyrosine Kinase Inhibitors Forecast
    • 12.7 Central & South America Tyrosine Kinase Inhibitors Forecast
    • 12.8 Middle East and Africa Tyrosine Kinase Inhibitors Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Tyrosine Kinase Inhibitors Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Tyrosine kinase inhibitors are small molecules that bind to the receptor site of the kinase enzyme available at cell surface.
      The global tyrosine kinase inhibitors market is expanding owing to high prevalence and increase in incidence of cancer across the globe.
      The global Tyrosine Kinase Inhibitors market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Tyrosine Kinase Inhibitors market based on company, product type, end user and key regions.

      This report studies the global market size of Tyrosine Kinase Inhibitors in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Tyrosine Kinase Inhibitors in these regions.
      This research report categorizes the global Tyrosine Kinase Inhibitors market by top players/brands, region, type and end user. This report also studies the global Tyrosine Kinase Inhibitors market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      AstraZeneca
      Pfizer
      Novartis
      Bristol-Myers Squibb
      Bayer
      Boehringer Ingelheim International
      F. Hoffmann-La Roche
      Johnson & Johnson
      Eisai

      Market size by Product
      BCR-ABL Tyrosine Kinase Inhibitor
      Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
      Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
      Market size by End User
      Chronic Myeloid Leukemia (CML)
      Lung Cancer
      Breast Cancer
      Renal Cell Cancer
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Tyrosine Kinase Inhibitors market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Tyrosine Kinase Inhibitors market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Tyrosine Kinase Inhibitors companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Tyrosine Kinase Inhibitors submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Tyrosine Kinase Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Tyrosine Kinase Inhibitors market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now